- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on Mod GRF 1-29 (CJC-1295 without DAC)
Mod GRF 1-29 — also called CJC-1295 without DAC, tetrasubstituted GRF(1-29), or sermorelin's more stable cousin — is a synthetic analog of the first 29 amino acids of natural GHRH (growth hormone-releasing hormone), which is the active core of the molecule. Developed by ConjuChem in the early 2000s alongside the DAC version, Mod GRF 1-29 has four strategic amino acid substitutions that protect it from enzymatic breakdown without adding the albumin-binding complex that extends the DAC version's half-life to days.
Mechanism in plain English
It mimics GHRH at pituitary GHRH receptors, telling the pituitary to release growth hormone in a natural pulsatile pattern. Half-life sits around 30 minutes, which is the entire design philosophy: long enough to trigger a clean GH pulse, short enough to let receptors reset between doses. This pulsatility is what separates Mod GRF from its DAC counterpart and is why most modern protocols favor it.
What it's used for
People take it for the full GH-axis benefits: better sleep, faster recovery, improved body composition, skin and joint quality. First effects show up at 2-3 weeks (usually sleep), visual body changes at 2-3 months. Almost always stacked with a GHRP like Ipamorelin — the combo is synergistic because the two peptides activate different receptors, producing a bigger pulse than either alone.
Upsides and downsides
Main upside — pulsatile signaling keeps the endocrine system responsive long-term. Receptors recover between doses, GH pulses resemble the body's natural pattern, and downregulation is minimal compared to constant-elevation alternatives. It's the "clean version" of GHRH stimulation.
Main downside — injection frequency. Short half-life means 2-3 injections per day for proper pulsatile effect, which creates adherence problems for anyone who travels, works shifts, or hates needles.
Typical protocol
Protocols run 100 mcg subcutaneously 1-3 times per day on an empty stomach — classic timing is morning fasted, pre-workout, and before bed. Cycles run 8-16 weeks with equivalent breaks. The before-bed dose matters most because it amplifies your natural nocturnal GH pulse.
Who should skip it
- Anyone with active cancer.
- Anyone with diabetic retinopathy.
- Anyone with uncontrolled diabetes.
- Anyone with a condition involving abnormal tissue growth.
Regulatory status
Banned by WADA under category S2 as a growth hormone secretagogue — detection methods exist and work. Not approved as a medication; sold as a research chemical.
If you've spent any time looking at peptide protocols, you've probably noticed something strange: both "CJC-1295" and "Modified GRF 1-29" are often sold under the same product name, by the same suppliers, in the same vials — and they're frequently treated as if they're interchangeable. They're not.
They're related, they have the same 29-amino-acid core sequence, and they do the same thing at the receptor level. But one has a tiny molecular attachment that extends its half-life from 30 minutes to nearly a week. The other doesn't. That single structural difference completely changes how the peptide is used, dosed, and — most importantly — what it does to your body's natural hormone rhythms.
Modified GRF 1-29 is the shorter-acting version. It's also, by most practitioners' view, the more physiologically elegant one — the one that works with your body's natural growth hormone pulsatility instead of overriding it.
Modified GRF 1-29: what it is and how it works in a nutshell
Modified GRF 1-29 (abbreviated Mod GRF 1-29, originally called tetrasubstituted GRF 1-29) is a synthetic 29-amino-acid peptide analog of natural growth hormone-releasing hormone (GHRH). It's identical to CJC-1295 without the DAC attachment — same core sequence, same four amino acid substitutions, but without the drug affinity complex that binds to albumin.
The relationship between Mod GRF 1-29 and related peptides is worth understanding:
- Natural GHRH — 44-amino-acid peptide produced by the hypothalamus. Half-life under 7 minutes.
- Sermorelin / GRF 1-29 — the first 29 amino acids of GHRH. Turns out to be fully functional. Half-life about 10-20 minutes.
- Modified GRF 1-29 — the same 29-amino-acid sequence, but with 4 strategic substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) that make it resistant to DPP-4 enzyme degradation. Half-life extends to about 30 minutes.
- CJC-1295 (with DAC) — Mod GRF 1-29 with an added lysine and drug affinity complex that binds albumin. Half-life jumps to 6-8 days [1].
Same drug, same mechanism, progressively extended pharmacokinetics. Mod GRF 1-29 sits in the middle — stable enough to actually work, short enough to preserve natural pulsatility.
Like its cousins, Mod GRF 1-29 is not FDA-approved for any indication. It exists in the research chemical and anti-aging clinic space.
Modified GRF 1-29 mechanism of action: what it actually does in the body
The structural modifications solve a specific problem. Natural GHRH has three amino acids vulnerable to dipeptidyl peptidase-4 (DPP-4) — an enzyme that snips peptides apart in the bloodstream within minutes. The Mod GRF 1-29 substitutions block those cleavage sites:
- D-Alanine at position 2 — replaces L-alanine with its mirror-image form, which DPP-4 doesn't recognize. This is the main stability upgrade.
- Glutamine at position 8 — replaces asparagine, reducing deamidation
- Alanine at position 15 — replaces glycine, reducing conformational flexibility that enzymes exploit
- Leucine at position 27 — replaces methionine, preventing oxidation during manufacturing and storage
Combined, these modifications make the peptide roughly 3x more stable than Sermorelin and give it enhanced receptor binding affinity. The result is a GHRH analog that actually makes it to the pituitary intact and produces a meaningful GH pulse.
The mechanism at the pituitary. Mod GRF 1-29 binds the GHRH receptor (GHRHR) on pituitary somatotroph cells — a class B G protein-coupled receptor. Activation triggers:
- Adenylate cyclase activation → increased intracellular cAMP
- Protein kinase A (PKA) phosphorylation
- Calcium mobilization
- GH synthesis gene transcription (a slower effect than release)
- Exocytosis of stored GH from secretory granules
Peak GH release happens within 15-30 minutes of injection. Levels return toward baseline within 2-3 hours. This pulse pattern is structurally similar to a natural GH pulse — which is the whole point.
Why pulsatility matters. Your body releases GH in bursts — typically 5-10 pulses per day, with the biggest occurring in deep sleep. Your tissues are designed to respond to this pulsed pattern with intervening low-GH "valleys." When you flatten the pattern with sustained high GH (from CJC-1295 DAC or exogenous HGH), you may lose some of the tissue sensitivity that comes from natural pulses. You also risk pituitary desensitization over time.
Mod GRF 1-29's short half-life is a feature, not a bug. It amplifies the GH pulse when injected, then gets out of the way. This is considered more physiological than sustained GH elevation — closer to how your body actually works. It's also why Mod GRF 1-29 is the preferred GHRH analog among clinicians who prioritize pulsatile rhythm over injection convenience.
Who uses Modified GRF 1-29 and what for
- Adults over 30 pursuing physiological GH optimization — the core user group. People who want measurable IGF-1 elevation and sleep quality improvements without permanently flooding the system with GH.
- Biohackers and anti-aging patients prioritizing natural pulsatility — specifically chosen over the DAC version by those who've read the clinical literature and prefer short-acting peptides.
- Bodybuilders during cutting phases — when preserving natural GH rhythms and receptor sensitivity matters more than convenience.
- Clinicians in regenerative and functional medicine — increasingly preferred as the GHRH side of a GHRH + GHRP stack. Usually paired with Ipamorelin for the classic "physiological" approach.
- Athletes who've experienced side effects on CJC-1295 DAC — water retention, persistent tingling, or other GH-bleed symptoms tend to diminish on the no-DAC version.
Realistic expectations over 8-12 weeks: measurable IGF-1 elevation on bloodwork, improved sleep quality within 2-3 weeks, gradual body composition improvements, better recovery. Effects are cumulative. The same magnitude of benefit as the CJC-1295 DAC version in most users — just delivered as sharp pulses rather than sustained elevation.
What WON'T happen: dramatic acute effects (you won't feel different 10 minutes after injection), once-weekly convenience (you'll inject at least daily, often 2-3x daily), fat loss or muscle gain without training and nutrition alignment.
What Modified GRF 1-29 stacks with: popular combinations
Mod GRF 1-29 is almost always used in a stack — it's the GHRH half of a GHRH+GHRP combination, and stacking with a GHRP is what makes the synergy story work.
- Mod GRF 1-29 + Ipamorelin — the gold standard combination. Mod GRF opens the GHRH receptor, Ipamorelin opens the ghrelin receptor, both pituitary switches fire together for substantially more GH release than either peptide alone. This is the classic "clean" peptide stack for most users.
- Mod GRF 1-29 + GHRP-2 — stronger GH pulse than the Ipamorelin combo, but with modest cortisol and prolactin crossover from GHRP-2. Used when maximum potency matters more than hormonal cleanness.
- Mod GRF 1-29 + GHRP-6 — adds aggressive appetite stimulation. For people specifically wanting to increase food intake during mass phases.
- Mod GRF 1-29 + BPC-157 or TB-500 — for recovery-focused protocols combining GH support with direct tissue repair.
Generally avoided with: CJC-1295 DAC (redundant — they hit the same receptor), exogenous GH (defeats the purpose of endogenous stimulation).
Modified GRF 1-29 side effects and risks
Side effect profile is milder than CJC-1295 DAC because you're producing pulsed GH release rather than sustained elevation. Most side effects are consequences of the GH pulse itself and resolve between doses.
- Transient flushing — within minutes of injection, brief, harmless
- Mild tingling or lightheadedness — especially initially, self-limiting
- Injection site reactions — small bumps, redness, transient
- Mild hunger increase — some users, less than with GHRP-containing stacks
- Very mild water retention — first 1-2 weeks, resolves
Also occasionally reported: head fullness sensations after injection, slight fatigue early in protocols.
Compared to CJC-1295 DAC: most users report fewer persistent side effects (less tingling in extremities, less water retention, less morning puffiness) because the peptide clears between doses. This cleaner subjective experience is part of why many clinicians now prefer it.
Who should be cautious or avoid:
- Anyone with active or recent history of cancer (GH/IGF-1 elevation concern)
- Diabetics with poor glucose control
- Pregnant or breastfeeding women
- Anyone under 25 without medical necessity
- Competitive athletes — Mod GRF 1-29 falls under the WADA Prohibited List (S2) for growth hormone releasing factors [2]
How to use and store Modified GRF 1-29
Subcutaneous injection only. Oral bioavailability is essentially zero.
Typical protocols:
- Dose: 100-300 mcg per injection
- Frequency: 1-3 times daily. Most common: twice daily, or three times daily when paired with GHRP.
- Cycle: 8-12 weeks, followed by 4+ week break (though many users run it continuously given the clean profile)
- Timing: on an empty stomach, 2+ hours after eating. Insulin and high blood glucose blunt GH release significantly — food timing matters more than people realize.
- Best injection windows: 30-60 minutes before bed (aligns with natural nightly GH surge), post-workout, and morning fasted
Why 2-3x daily: short half-life. Single daily dosing captures just one GH pulse. Spreading injections across the day captures multiple natural release windows and produces meaningfully better IGF-1 elevation over time.
When stacked with Ipamorelin: identical dose (100-300 mcg of each peptide) injected together. The duo-blend vials sold by some suppliers are pre-mixed formulations of this exact stack.
Storage: lyophilized form in freezer. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 30 days. Don't freeze the reconstituted solution.
Labs and monitoring during a Modified GRF 1-29 cycle
Before: IGF-1, fasting glucose, HbA1c, basic metabolic panel. Optional: fasting insulin.
During (week 4-6): IGF-1 and fasting glucose. IGF-1 should show measurable elevation — if it hasn't moved, check timing (injection too close to meals?), product quality, or dose.
After: repeat IGF-1 and glucose 2-4 weeks post-cycle.
Target: IGF-1 in the upper normal range for your age, not pushed above reference range.
Modified GRF 1-29 vs alternatives: what's different
- CJC-1295 with DAC — same peptide, albumin-bound, 6-8 day half-life. Once-weekly dosing vs daily. Sustained GH elevation vs pulsatile. More convenient, less physiological.
- Sermorelin — the unmodified natural GRF 1-29. 10-20 minute half-life. Needs frequent dosing, milder effect, older and cheaper.
- Tesamorelin — FDA-approved GHRH analog for HIV lipodystrophy. Different amino acid modifications, stronger for visceral fat specifically, much more expensive, prescription-only.
- Ipamorelin alone — works through ghrelin receptor, not GHRH receptor. Complementary, not substitutive — most users do both together rather than choosing one.
Mod GRF 1-29's distinguishing feature: the best physiological GHRH analog available — stable enough to work, short enough to preserve pulsatility, without the GH bleed concern of the DAC version. For long-term wellness use where you want to amplify your own hormone rhythms rather than override them, this is typically the better choice.
Myths about Modified GRF 1-29
- "CJC-1295 and Modified GRF 1-29 are the same thing." They have the same core sequence but dramatically different pharmacokinetics. Conflating them leads to wrong dosing protocols (once-weekly vs daily), wrong side effect expectations, and sometimes wrong product entirely from suppliers who don't label clearly. Read the spec sheet — if it says "DAC" anywhere, it's the long-acting version.
- "Short half-life means weaker results." The total GH output over a day with properly-timed Mod GRF 1-29 dosing (2-3x daily paired with a GHRP) is comparable to what the DAC version produces. The shape of the GH curve is different (pulses vs sustained elevation), but the area under the curve — and the downstream IGF-1 response — is similar in properly-dosed protocols.
Sources
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ — establishes the pharmacokinetic distinction between DAC and no-DAC variants.
- World Anti-Doping Agency (WADA). Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. https://www.wada-ama.org — Modified GRF 1-29 classification in competitive sport.
- Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ — documents how pulsatility differs between DAC and short-acting GHRH analogs.
- Walker, R. F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307-308. — comparative framework for short-acting GHRH analogs in adult GH optimization.
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.-P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism, 291(6), E1290-E1294. — relevant animal data for the GHRHR signaling pathway.
- Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. — foundational characterization of the GHRP side of the classic Mod GRF 1-29 + Ipamorelin stack.
Mod GRF (1-29) / CJC-1295 no DAC Dosage Guide
Mod GRF (1-29), also sold as CJC-1295 no DAC, is a synthetic 29-amino-acid GHRH analog with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that enhance enzymatic stability while maintaining the short ~30-minute half-life of endogenous GHRH. Unlike the DAC version, it produces sharp, discrete GH pulses rather than sustained baseline elevation. This guide is aimed at users prioritizing natural pulsatile GH release for fat loss, body recomposition, recovery, and sleep quality — particularly those pairing it with a GHRP like Ipamorelin for synergistic release. Dosing below combines the Teichman CJC-1295 clinical pharmacokinetic data, the original GRF(1-29) dose-response studies (1–2 mcg/kg), and the long-standing community protocol built around 100 mcg per injection.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | Once daily, SC, pre-bed fasted | First 2 weeks; assess response |
| Standard | 100 mcg | Twice daily (AM fasted + pre-bed), SC | Most common community protocol |
| Intermediate | 100 mcg | 3 times daily (AM, post-workout, pre-bed), SC | Three daily GH pulses |
| Aggressive | 200 mcg | 3 times daily, SC | Upper range; receptor saturation near 100 mcg |
| Weight-based reference | 1–2 mcg/kg | Per injection, SC | Original GRF(1-29) clinical research range |
Doses also shift depending on the specific goal. The same peptide used for general anti-aging versus athletic recomposition can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Fat loss / body recomposition | 100 mcg | Twice daily, SC fasted | 12 weeks on / 4 weeks off |
| Muscle gain / athletic recovery | 100 mcg | 3 times daily, SC fasted | 12–16 weeks on / 4 weeks off |
| Sleep quality / anti-aging | 100 mcg | Once daily, SC pre-bed | 8–12 weeks on / 4 weeks off |
| Stacked with Ipamorelin (classic) | 100 mcg each | Twice daily, same syringe SC | 8–12 weeks |
| Stacked with Ipamorelin (aggressive) | 100 mcg each | 3 times daily, same syringe SC | 12–16 weeks |
| Stacked with GHRP-2 or GHRP-6 | 100 mcg each | 2–3 times daily, same syringe SC | 8–12 weeks |
Inject on an empty stomach with at least 2 hours since your last meal, and wait 20–30 minutes before eating — elevated insulin from carbohydrates completely blunts the GH pulse and wastes the injection regardless of dose. Stick to 100 mcg per injection rather than escalating doses; GHRH receptor saturation sits near this dose, so higher amounts primarily increase water retention, facial flushing, and injection-site irritation without proportional GH release. Absolute contraindications include active cancer diagnosis (IGF-1 elevation is mitogenic), diabetic retinopathy, and pregnancy — anyone with a cancer history should consult an oncologist before any dose. Unlike CJC-1295 DAC, the short half-life means effects wash out within hours, giving more flexibility to stop or adjust quickly.
Mod GRF (1-29) Storage Guide: How to Keep Your Research Peptide Stable and Effective
Mod GRF (1-29), also known as CJC-1295 no DAC, ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its modified GHRH structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a frost-free freezer with temperature swings, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Mod GRF (1-29), often sold as "CJC-1295 without DAC," is a synthetic peptide made from the first 29 amino acids of your body's natural growth hormone-releasing hormone (GHRH). Four of those amino acids have been swapped out to make the peptide more stable, resistant to enzymatic breakdown, and more potent at binding to GHRH receptors. It is the same active molecule as the unmodified portion of CJC-1295, but without the Drug Affinity Complex (DAC) that extends the half-life. It is sold strictly as a research chemical and is not approved by the FDA for human use.
Mod GRF (1-29) binds to growth hormone-releasing hormone receptors (GHRHR) on the somatotroph cells of the pituitary gland. This binding activates adenylate cyclase, raises intracellular cAMP, and triggers the pituitary to release a pulse of growth hormone (GH). That GH then travels to the liver, where it stimulates production of IGF-1, which drives muscle growth, fat breakdown, and tissue repair. Crucially, it only amplifies your body's own GH pulses — it does not replace them — which preserves natural feedback regulation.
Both peptides share the same 29-amino-acid core, but CJC-1295 with DAC has an added Drug Affinity Complex that binds it to albumin in the blood. This single modification stretches the half-life from about 30 minutes (Mod GRF) to roughly 6–8 days (CJC-1295 DAC). The DAC version gives a constant, sustained "bleed" of GH, while Mod GRF produces a sharp, clean pulse that mimics natural GH release. Many clinicians consider Mod GRF more physiological, while CJC-1295 DAC is more convenient but may cause receptor desensitization.
By triggering natural GH and IGF-1 pulses, Mod GRF (1-29) is associated with improved lean muscle growth, reduced body fat, better recovery from training or injury, deeper sleep (especially slow-wave sleep), improved skin quality, and stronger connective tissue. Users also report improved energy, mood, and libido. It's important to be honest: most of these benefits are reported from user experience and clinical observation rather than large randomized trials, so the evidence is suggestive rather than conclusive.
Commonly used research doses are 100 mcg per injection, administered subcutaneously 1–3 times per day. The "saturation dose" concept — where additional peptide above 100 mcg doesn't produce a bigger GH pulse — means there's little reason to inject more at once. Most protocols involve one injection before bed (to amplify the natural nighttime GH peak) and sometimes additional doses after training or on an empty stomach in the morning. Cycles typically run 8–12 weeks with breaks to avoid receptor desensitization.
Mod GRF and the ghrelin-mimetic peptides work on two completely separate pathways, and combining them produces far more GH release than either alone. Mod GRF (1-29) increases the amplitude of each GH pulse, while peptides like Ipamorelin, GHRP-2, or GHRP-6 increase pulse frequency and suppress somatostatin (the body's GH "brake"). The classic stack is Mod GRF + Ipamorelin at 100 mcg each, injected together — this is often called a "CJC + Ipa" stack and is the most popular peptide combination in this category.
Mod GRF (1-29) is generally well tolerated, and side effects tend to be milder than with CJC-1295 DAC because GH levels aren't chronically elevated. Commonly reported effects include a brief flushing or warmth after injection, lightheadedness, tingling in the hands (a GH-related symptom), temporary headache, injection-site redness, and occasionally vivid dreams. More significant side effects — water retention, joint discomfort, numbness, and changes in insulin sensitivity — are usually associated with overdosing or long-term use. Serious adverse events in short-term use are rare.
Most users report noticeable changes in sleep quality within the first 1–2 weeks, which is often the first indicator the peptide is working. Improvements in recovery, skin quality, and general wellbeing typically appear by weeks 3–6. Visible changes in body composition — more lean muscle, less body fat — generally emerge over 8–12 weeks of consistent use combined with appropriate training and nutrition. Older users with naturally declining GH levels tend to notice effects more dramatically than younger users.
Mod GRF (1-29) is not approved as a prescription drug by the FDA, EMA, or most other regulators. It is sold legally as a "research chemical" labeled "not for human consumption," though some licensed clinicians can obtain similar peptides through compounding pharmacies. Possessing it for personal use exists in a legal grey zone that varies by country. It is also banned by WADA and virtually every major sports organization, so competitive athletes using it risk sanctions and can be detected in modern drug tests.
The naming is genuinely confusing and has been a source of debate in the peptide community. Technically, the original CJC-1295 molecule developed by ConjuChem includes a lysine residue that attaches to DAC — removing just the DAC but keeping the lysine produces a different molecule than Mod GRF. Most peptide vendors use the two names interchangeably, but purists argue "CJC-1295 no DAC" is inaccurate and the correct term is "Modified GRF (1-29)" or "tetrasubstituted GRF (1-29)." In practice, the peptide being sold under both names is almost always the same thing.
